BAXTER-LACTATED RINGER’S INJECTION USP

Country: Singapore

Language: English

Source: HSA (Health Sciences Authority)

Active ingredient:

Calcium Chloride Dihydrate; Potassium Chloride; Sodium Chloride; Sodium Lactate Solution

Available from:

BAXTER HEALTHCARE (ASIA) PTE LTD

ATC code:

B05BB01

Pharmaceutical form:

INFUSION, SOLUTION

Composition:

Calcium Chloride Dihydrate 20mg per 100mL; Potassium Chloride 30mg per 100mL; Sodium Chloride 600mg per 100mL; Sodium Lactate Solution 310mg per 100mL

Administration route:

INTRAVENOUS

Prescription type:

General Sale List

Manufactured by:

Baxter Healthcare Philippines, Inc

Authorization status:

ACTIVE

Authorization date:

2022-09-14

Summary of Product characteristics

PHRML00107
Lactated Ringer's Solution
Lactated Ringer's Injection, USP
in Viaflex
®
Plastic Container
The Viaflex
®
plastic container is fabricated from a specially formulated polyvinyl
chloride (PL 146
®
Plastic).
The amount of water that can permeate from inside the container into
the overwrap is insufficient to affect
the solution significantly. Solutions in contact with the plastic
container can leach out certain of its chemical
components in very small amounts within the expiration period, e.g.,
di-2-ethylhexyl phthalate (DEHP), up
to 5 parts per million. However, the safety of the plastic has been
confirmed in tests in animals according to
USP biological tests for plastic containers as well as by tissue
culture toxicity studies.
CLINICAL PHARMACOLOGY
Lactated Ringer’s Injection, USP has value as a source of water and
electrolytes. It is capable of inducing
diuresis depending on the clinical condition of the patient.
Lactated Ringer’s Injection, USP produces a metabolic alkalinizing
effect. Lactate ions are metabolized
ultimately to carbon dioxide and water, which requires the consumption
of hydrogen cations.
INDICATIONS AND USAGE
Lactated Ringer’s Injection, USP is indicated as a source of water
and electrolytes or as an alkalinizing agent.
CONTRAINDICATIONS
Lactated Ringer’s Injection, USP is contraindicated in:
•
Newborns (
≤
28 days of age) receiving concomitant treatment with ceftriaxone, even
if separate infusion
lines are used due to the risk of fatal ceftriaxone-calcium salt
precipitation in the neonate’s bloodstream.
•
Patients older than 28 days, including adults, administered
ceftriaxone simultaneously through the same
infusion line (e.g., via a Y-connector). If the same infusion line is
used for sequential administration, the
line must be thoroughly flushed between infusions with a compatible
fluid.
•
Patients with known hypersensitivity to sodium lactate (see WARNINGS).
WARNINGS
Potassium Content
The potassium concentration in Lactated Ringer’s Injection, USP is
similar to